Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation

Completed

• Conditions: Breast Neoplasms

• Registration Number: NCT02860585
• Lead Sponsor: Institut Paoli-Calmettes

Brief Summary

The objective of this study was to evaluate the outcome of patients affected with different subtypes of metastatic breast cancer following treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09-27
• Primary Completion: 2016-02-29
• Study Completion: 2016-02-29
• Status Verified: 2016-08
• Study First Submitted: 2016-08-04
• Study First Submitted QC: 2016-08-04
• Study First Posted: 2016-08-09
• Last Update Submitted: 2017-09-25
• Last Update Posted: 2017-09-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 235

Inclusion Criteria

• Age>18 years
• Metastatic breast Cancer
• Treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation between 2003 and 2012

Exclusion Criteria

• Lack of follow-up data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival according to Immunohistochemical subtypes .	8 years

Secondary Outcome Measures

Name	Time	Method
Progression free Survival according to Immunohistochemical subtypes .	8 years

Trial Locations

Locations (1)

Institut Paoli-Calmettes; 🇫🇷 Marseille, France